2nd Quarter - Amendment

PFIZER INC. for PFIZER INC.

Firm
Client
Income
—
Expenses
$3,610,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 19, 2011 $3,550,000 Replaced
2nd Quarter - Amendment (this page) May 18, 2012 $3,610,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trans Pacific Partnership Negotiations Japan Market Access and Regulatory Issues US-Korea Free Trade Agreement Israel Patent Issues Brazil IP - WTO Case Australian FTA Implementation Chile IP Issues - FTA Implementation

LobbyistCovered position, as disclosed
JOSEPH DAMOND —

Contacted: Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Food & Drug Administration (FDA); SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Counterfeit Pharmaceuticals Expert Patent Courts Pilot Programs Patent Settlements Patent Reform Act, 2011 Protecting Consumer Access to Generic Drugs S. 27, Preserve Access to Affordable Generics S.23, America Invents Act, 2011 H.R. 1249, America Invents Act, 2011

LobbyistCovered position, as disclosed
KEN W COLE —
JENNIFER DUCK —
JOHN PAUL HALLIWELL —
ANGELA WALKER RIEMER —
MARY BRIDGET WALSH —
JENNIFER SWENSON WALTON —

Contacted: Food & Drug Administration (FDA); State, Dept of (DOS); Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Executive Office of the President (EOP); Commerce, Dept of (DOC)

Bills named: S. 23 (112th), S. 27 (112th), H.R. 1249 (112th)

Health Issues HCR

Health Care Reform Comparative Effectiveness Research Prescription Drug User Fee Act (PDUFA) Follow on Biologics Antibiotic Incentives Tax Extenders Antimicrobial Resistance Strategies to Address Antimicrobial Resistance Senate Labor - HHS Appropriations bill, with regard to funding of the 317 Program H.R. 965, The Preservation of Antibiotics for Medical Treatment Act, 2011 H.R. 979, FEHBP Priscription Drug Integrity, Transparency and Cost Savings Act, 2011 S. 668, Health Care Bureacrats Elimination Act, 2011 S. 1094, Combating Autism Act

Contacted: Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); State, Dept of (DOS)

Bills named: S. 668 (112th), H.R. 979 (112th), H.R. 965 (112th), S. 1094 (112th)

Medicare/Medicaid MMM

Medicare Prescription Drug Benefit Medicare Rebates Medicare Coverage Medicare Part D Average Manufacturer Price Regulation Patient Protection and Affordable Care Act Implementation Debt Ceiling and Part D H.R. 452, Medicare Decision Accountability Act, 2011 S. 1206, Medicare Drug savings Act

LobbyistCovered position, as disclosed
KEN W COLE —
JENNIFER DUCK —
JOHN PAUL HALLIWELL —
ANGELA WALKER RIEMER —
MARY BRIDGET WALSH —
JENNIFER SWENSON WALTON —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); State, Dept of (DOS); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); SENATE; Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 452 (112th), S. 1206 (112th)

Consumer Issues/Safety/Products CSP

Importation Certified Importer Program Dextromethorphan Distribution Dextromethorphan Abuse Reduction The Food, Drug and Cosmetic Globalization Act ELDU Ban on Cephalosporin PSE Issues OTC Products in Flexible Spending Account H.R. 741, Act to Prohibit the Marketing of Authorized Generic Drugs, 2011 S. 373, Fair Prescription Drug Competition Act, 2011

LobbyistCovered position, as disclosed
JOHN PAUL HALLIWELL —
JENNIFER SWENSON WALTON —

Contacted: SENATE; Patent & Trademark Office (PTO); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP)

Bills named: H.R. 741 (112th), S. 373 (112th)

Taxation/Internal Revenue Code TAX

Repatriation Deferral Deferral for active-financing income- extension S. 1203, R& D Tax Credit Extension and Enhancement H.R. 422, R&D Tax Credit Extension and Enhancement H.R. 2098, CFC Look Through Extension H.R. 1834, Freedom to Invest Act

LobbyistCovered position, as disclosed
MARIA CINO —
KEN W COLE —
JENNIFER DUCK —
ANTHONY PRINCIPI —
CAROLINE MOODY SCHELLHAS New —

Contacted: Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); State, Dept of (DOS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2098 (112th), H.R. 422 (112th), H.R. 1834 (112th), S. 1203 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.